Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06442436 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06442436 · ClinicalTrials.gov record · last posted 2026-08-05

A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

StatusActive, Not Recruiting
PhasePhase 1
Started2024-07-24
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemtabrutinib (MK-1026) following a single oral dose of nemtabrutinib in participants with moderate hepatic impairment to that of healthy matched control participants and to evaluate the safety and tolerability of nemtabrutinib.

Protocol amendment history 1 change detected by DataLookout

2026-08-06
Enrollment closed, study ongoing
Trial Details
NCT Number NCT06442436
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Hepatic Impairment (HI)
Enrollment 32 participants
Start Date 2024-07-24
Primary Completion 2026-09-14 (estimated)
Study Completion 2026-09-14 (estimated)
Updated on ClinicalTrials.gov 2026-08-05